Abstract
Inhibition of the HSP90 chaperone leads to degradation of the HER2 receptor. The HSP90 inhibitor tanespimycin in combination with trastuzumab is active in patients with HER2-overexpressing metastatic breast cancer. This combination is one of several HER2-targeted therapies that will significantly improve the outcome of patients with this subtype of breast cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 4919-4921 |
Number of pages | 3 |
Journal | Clinical Cancer Research |
Volume | 17 |
Issue number | 15 |
DOIs | |
State | Published - Aug 1 2011 |
ASJC Scopus subject areas
- Oncology
- Cancer Research